Gịnị bụ Glecaprevir na Pibrentasvir: Ojiji, Ọgwụ, Mmetụta Akụkụ na Ihe Ọzọ

Glecaprevir na pibrentasvir bụ ọgwụ mgbochi nje na-ejikọta ọnụ nke na-agwọ ọrịa hepatitis C, ọrịa nje na-emetụta imeju gị. Ọgwụ a nwere ọgwụ abụọ dị ike na-arụkọ ọrụ ọnụ iji kwụsị nje hepatitis C ịba ụba n'ime ahụ gị. Chee ya dị ka otu ndị a tụrụ anya nke na-aga kpọmkwem na nje ahụ ebe ọ na-ahapụ mkpụrụ ndụ gị dị mma naanị ya.

Ọ bụrụ na achọpụtala gị na hepatitis C, ị nwere ike imetụta okwu ahụike na nhọrọ ọgwụgwọ. Ọgwụgwọ a jikọtara ọnụ enyerela ọtụtụ puku mmadụ aka ihichapụ nje ahụ n'ime sistemụ ha, na-abụkarị n'ime izu 8 ruo 12. Ozi ọma bụ na ọgwụgwọ a dị ezigbo irè ma ndị ọrịa na-anabata ya nke ọma.

Gịnị bụ Glecaprevir na Pibrentasvir?

Glecaprevir na pibrentasvir bụ ọgwụ ndenye ọgwụ nke na-ejikọta ọgwụ mgbochi nje abụọ na-arụ ọrụ ozugbo n'ime otu mbadamba. Glecaprevir na-egbochi enzyme a na-akpọ NS3/4A protease, nke nje hepatitis C chọrọ iji mụgharịa. Pibrentasvir na-elekwasị anya na enzyme dị iche nke a na-akpọ NS5A, nke na-enyere nje ahụ aka ịgbakọ ụdị onwe ya ọhụrụ.

Mgbe ọgwụ abụọ a na-arụkọ ọrụ ọnụ, ha na-emepụta nchebe dị ike megide hepatitis C. A na-egbochi nje ahụ na nzọụkwụ abụọ dị iche iche nke ndụ ya, na-eme ka ọ ghara ikwe omume ka ọ gaa n'ihu na-agbasa n'ime imeju gị. Ụzọ abụọ a bụ ihe mere njikọ ahụ ji dị irè n'ịsachapụ ọrịa ahụ.

Ị nwere ike ịma ọgwụ a site na aha ụdị ya, nke anyị ga-atụle n'isiokwu a. Njikọ ahụ na-abịa dị ka mbadamba ọnụ nke ị na-aṅụ site n'ọnụ, na-eme ka ọgwụgwọ dị mma ma na-achịkwa site n'ụlọ.

Gịnị ka a na-eji Glecaprevir na Pibrentasvir eme ihe?

Ọgwụ a na-agwọ ọrịa nje hepatitis C na-adịgide adịgide n'ime ndị okenye na ụmụaka dị afọ 3 na karịa. Ọ na-arụ ọrụ megide ụdị nje hepatitis C isii niile, nke pụtara na dọkịta gị ekwesịghị ikpebi ụdị nje gị tupu ịmalite ọgwụgwọ. Nke a na-enyere aka karịsịa n'ihi na ọ na-eme ka usoro ọgwụgwọ dị mfe.

Dọkịta gị nwere ike ịnye ngwakọta a ma ọ bụrụ na a gwọbeghị gị maka hepatitis C mbụ, ma ọ bụrụ na ọgwụgwọ ndị gara aga arụghị ọrụ. Ọ na-arụkwa ọrụ maka ndị nwere cirrhosis imeju, ọ gwụla ma imeju gị na-arụ ọrụ nke ọma. Ọgwụ ahụ nwere ike ihichapụ nje ahụ ọbụna n'ọnọdụ ebe nje ahụ dịla ọtụtụ afọ.

Ụfọdụ ndị na-anata ọgwụgwọ a yana ribavirin, ọgwụ antiviral ọzọ, dabere na ọnọdụ ha. Onye na-ahụ maka ahụike gị ga-ekpebi ụzọ kacha mma dabere na akụkọ ahụike gị, ọnọdụ imeju gị, na ụdị hepatitis C ị nwere.

Kedu ka Glecaprevir na Pibrentasvir si arụ ọrụ?

A na-ewere ngwakọta ọgwụ a dị ka ọgwụgwọ siri ike, nke dị irè maka hepatitis C. Ọgwụ abụọ ahụ na-arụ ọrụ site n'itinye aka na usoro dị iche iche na usoro mmepụta nke nje ahụ, na-akwụsị ya ka ọ ghara imepụta onwe ya. Mgbe nje ahụ enweghị ike ịmụgharị, usoro ahụ ji alụso ọrịa ọgụ gị nwere ike iji nwayọọ nwayọọ wepụ ihe nje dị na ahụ gị.

Glecaprevir na-eme dị ka mkpọchi nke dabara na enzyme NS3/4A protease nke nje ahụ, na-egbochi ya ịkpụ protein nje n'ụdị kwesịrị ekwesị. Na-enweghị protein nwere ụdị kwesịrị ekwesị, nje ahụ enweghị ike mezue ndụ ya. Ka ọ dị ugbu a, pibrentasvir na-akpaghasị protein NS5A, nke na-enyere aka ịhazi ma kwakọba ihe nje ọhụrụ.

Ihe mara mma nke ụzọ abụọ a bụ na ọ na-awakpo nje ahụ n'ebe abụọ dị mkpa n'otu oge. Ọbụna ma ọ bụrụ na nje ahụ gbalịrị ịmepụta nguzogide na otu ọgwụ, ọgwụ nke ọzọ na-aga n'ihu na-arụ ọrụ. Nke a na-eme ka o sie ike karị maka nje ahụ ịgbanahụ ọgwụgwọ, nke bụ ihe mere ọnụego ịga nke ọma ji dị elu na njikọta a.

Kedu ka m ga-esi ewere Glecaprevir na Pibrentasvir?

Ị kwesịrị iwere ọgwụ a dị ka dọkịta gị nyere iwu, na-abụkarị mbadamba atọ otu ugboro n'ụbọchị na nri. Iwere ya na nri na-enyere ahụ gị aka ịmịnye ọgwụ ahụ nke ọma ma na-ebelata ohere nke afọ iwe. Ị nwere ike iwere ya na ụdị nri ọ bụla, mana zere iwere ya na afọ efu.

Gbalịa iwere dose gị n'otu oge kwa ụbọchị iji nyere gị aka icheta ma debe ọkwa ọgwụ na-adịgide adịgide n'ime ahụ gị. Ị nwere ike ịhọrọ oge ọ bụla na-arụ ọrụ na usoro ihe omume gị, ma nke ahụ ọ̀ bụ n'ụtụtụ, nri ehihie, ma ọ bụ nri abalị. Ọtụtụ ndị na-ahụ na ọ dị mfe icheta mgbe ha na-ejikọta ya na nnukwu nri ha na-eri n'ụbọchị.

Mịnye mbadamba nkume ahụ dum na mmiri ma ọ bụ ihe ọṅụṅụ ọzọ. Ekwela ka ị gbarie, taa, ma ọ bụ gbajie mbadamba nkume ahụ, n'ihi na nke a nwere ike imetụta otú a na-amịnye ọgwụ ahụ. Ọ bụrụ na ị nwere nsogbu ịmịnye mbadamba nkume, gwa dọkịta gị gbasara atụmatụ nwere ike inye aka, mana emela ka mbadamba nkume ahụ gbanwee n'onwe ha.

Gaa n'ihu na-ewere ọgwụ ahụ ọbụna ma ọ bụrụ na ịmalite inwe mmetụta ka mma. Nje ahụ nwere ike ịdị na ahụ gị ọbụna mgbe ị na-enweghị mgbaàmà, yabụ ịmecha usoro zuru ezu dị mkpa iji kpochapụ ọrịa ahụ kpamkpam.

Ogologo oge ole ka m ga-ewere Glecaprevir na Pibrentasvir?

Ọtụtụ ndị na-ewere ọgwụ a maka izu 8 ruo 16, dabere na ọnọdụ ha. Dọkịta gị ga-ekpebi ogologo oge ọgwụgwọ ahụ dabere na ihe dị ka ma a gwọọla gị mbụ, ọnọdụ imeju gị, na otú ahụ gị si emeghachi omume na ọgwụ ahụ. Ozi ọma bụ na nke a bụ obere oge ọgwụgwọ ma e jiri ya tụnyere ọgwụgwọ hepatitis C ochie.

Ọ bụrụ na ị na-aṅụ ọgwụ ahụ maka oge mbụ ma enweghị cirrhosis, ị ga-achọ izu 8 nke ọgwụgwọ. Ndị nwere cirrhosis ma ọ bụ ndị gbalịrị ọgwụgwọ ndị ọzọ nwere ike ịchọ izu 12 ruo 16. Dọkịta gị ga-akọwa usoro oge gị kpọmkwem na ihe mere oge ahụ ji dị gị mma.

Ọ dị ezigbo mkpa iji mezue usoro ọgwụgwọ ahụ dum, ọbụlagodi na ị na-eche na ị dị mma kpamkpam. Ụmụ nje ahụ nwere ike zoo n'ime mkpụrụ ndụ imeju gị, na ịkwụsị ọgwụgwọ mbụ na-enye ya ohere ịlaghachi. Chee ya dị ka ị taking antibiotics maka ọrịa nje bacteria - ịkwesịrị imecha ndenye ọgwụ ahụ dum iji hụ na ọrịa ahụ apụọla kpamkpam.

Kedu Ihe Bụ Mmetụta Ọjọọ nke Glecaprevir na Pibrentasvir?

Ọtụtụ ndị na-anabata ọgwụ a nke ọma, mana dị ka ọgwụ niile, ọ nwere ike ịkpata mmetụta. Mmetụta ndị a na-ahụkarị na-adịkarị nro ma gụnye isi ọwụwa, ike ọgwụgwụ, na ọgbụgbọ. Mgbe ụfọdụ mgbaàmà ndị a na-akawanye mma ka ahụ gị na-emegharị na ọgwụ ahụ, na-emekarị n'ime izu ole na ole mbụ nke ọgwụgwọ.

Nke a bụ mmetụta ndị ị nwere ike ịnweta, na-eburu n'uche na ọtụtụ ndị enweghị mmetụta ọ bụla:

Mmetụta ndị a na-ahụkarị (na-emetụta ihe karịrị otu n'ime mmadụ 10):

• Isi ọwụwa nke nwere ike iyi ka nrụgide ma ọ bụ nrụgide
• Ike ọgwụgwụ ma ọ bụ inwe mmetụta ike gwụrụ karịa ka ọ dị na mbụ
• Ọgbụgbọ, karịsịa n'ime izu ole na ole mbụ

Mmetụta ndị na-adịkarịghị (na-emetụta 1 n'ime mmadụ 100):

• Afọ ọsịsa ma ọ bụ stool rụrụ arụ
• Ihe mgbu afọ ma ọ bụ ahụ erughị ala
• Ọgbụgbọ ma ọ bụ isi ọwụwa
• Nsogbu ihi ụra ma ọ bụ mgbanwe n'ụdị ihi ụra
• Ahụhụ akpụkpọ ahụ ma ọ bụ itching

Mmetụta dị ụkọ ma dị njọ (na-emetụta ihe na-erughị 1 n'ime mmadụ 1000):

• Nsogbu imeju siri ike, nke nwere ike ime ka akpụkpọ ahụ ma ọ bụ anya na-acha odo odo, mmamiri gbara ọchịchịrị, ma ọ bụ nnukwu mgbu afọ
• Mmeghachi omume nfụkasị ahụ siri ike nwere afụ ọnụ nke ihu, egbugbere ọnụ, ire, ma ọ bụ akpịrị
• Nnukwu ịda mbà n'obi ma ọ bụ mgbanwe mmetụta uche

Ọtụtụ mmetụta dị n'akụkụ ahụ na-achịkwa ma na-adịru nwa oge. Ọ bụrụ na ị nwere ahụ mgbu isi, gbalịa ịṅụkwu mmiri ma zuru ike nke ọma. Maka ọgbụgbọ, iri obere nri, nke a na-emekarị nwere ike inye aka. Otú ọ dị, kpọtụrụ dọkịta gị ozugbo ma ọ bụrụ na ị nwere nnukwu mgbu afọ, akpụkpọ ahụ gị ma ọ bụ anya gị na-acha odo odo, ma ọ bụ ihe ọ bụla na-egosi mmeghachi omume nfụkasị ahụ.

Ònye Kwesịrị Ịghara Iṅụ Glecaprevir na Pibrentasvir?

Ọgwụ a adabaghị maka onye ọ bụla, dọkịta gị ga-elebakwa anya na akụkọ ahụike gị nke ọma tupu ịnye ya. Ndị nwere nnukwu nsogbu imeju ma ọ bụ ụfọdụ ọnọdụ ahụike ndị ọzọ nwere ike ịchọ ọgwụgwọ dị iche iche. Nchekwa gị bụ ihe kacha mkpa, yabụ ọ dị mkpa ka gị na onye na-ahụ maka ahụike gị kwurịta ọnọdụ ahụike gị niile n'ihu ọha.

Ịkwesighi iṅụ ọgwụ a ma ọ bụrụ na ị nwere ọnọdụ ndị a:

Ihe mgbochi zuru oke (anaghị eji ya eme ihe na ọnọdụ ndị a):

• Ọdịda imeju siri ike ma ọ bụ cirrhosis decompensated
• A maara nfụkasị ahụ na glecaprevir, pibrentasvir, ma ọ bụ ihe ọ bụla dị na mbadamba nkume
• Iji ọgwụ ụfọdụ ugbu a nke na-emekọrịta ihe dị ize ndụ na ọgwụgwọ a

Ọnọdụ chọrọ nlezianya pụrụ iche:

• Ọrịa akụrụ dị nro ruo nke siri ike
• Akụkọ ihe mere eme nke ọrịa hepatitis B
• Afọ ime ma ọ bụ inye nwa ara
• Nnukwu nsogbu obi
• Akụkọ ihe mere eme nke nnukwu ịda mbà n'obi ma ọ bụ ọnọdụ ahụike uche

Mmekọrịta ọgwụ iji zere:

• Ụfọdụ ọgwụ mgbochi ọrịa dị ka carbamazepine ma ọ bụ phenytoin
• Ụfọdụ ọgwụ nje, karịsịa rifampin
• Ụfọdụ ọgwụ cholesterol
• Ụfọdụ ihe mgbakwunye ahịhịa, karịsịa St. John's wort

Na-agwa dọkịta gị mgbe niile gbasara ọgwụ niile, ihe mgbakwunye, na ngwaahịa ahịhịa ị na-ewere. Ọbụna ọgwụ ndị a na-ere n'elu counter nwere ike imetụta ọgwụgwọ a mgbe ụfọdụ, yabụ eziokwu zuru oke gbasara ihe niile ị na-eri dị mkpa maka nchekwa gị.

Aha Ụdị Glecaprevir na Pibrentasvir

Aha ụdị maka ọgwụ a jikọtara ọnụ bụ Mavyret na United States na ọtụtụ mba ndị ọzọ. N'ebe ụfọdụ, a nwere ike ịmara ya site na aha ụdị dị iche iche, mana ihe ndị na-arụ ọrụ na-anọgide otu. Ụlọ ahịa ọgwụ gị ga-enyekarị ọgwụ ahụ na nkwakọ ngwaahịa mbụ ya.

Mbadamba Mavyret bụ ihe nkiri kpuchiri ma na-acha pinki. Mbadamba ọ bụla nwere 100 mg nke glecaprevir na 40 mg nke pibrentasvir. A na-ejikarị mbadamba ahụ eme ihe na ngwugwu blister ma ọ bụ karama, dabere na ụlọ ahịa ọgwụ gị na ebe ị nọ.

Ọ bụrụ na ị na-eme njem ma ọ bụ na-enweta ndenye ọgwụ na ebe dị iche iche, ị nwere ike iji aha ụdị Mavyret ma ọ bụ aha generic glecaprevir na pibrentasvir. Ndị na-ahụ maka ahụike na ndị na-ere ọgwụ n'ụwa niile ga-amata aha abụọ ahụ maka ọgwụgwọ hepatitis C a.

Ụzọ Ọzọ nke Glecaprevir na Pibrentasvir

Ọtụtụ ọgwụgwọ hepatitis C dị irè dị ma ọ bụrụ na njikọta a adabaghị gị. Dọkịta gị nwere ike ịtụle ụzọ ndị ọzọ dabere na ụdị nje virus gị, ọnọdụ imeju, akụkọ ihe mere eme nke ọgwụgwọ, ma ọ bụ mmekọrịta ọgwụ nwere ike ime. Ụzọ ọ bụla ọzọ nwere uru na nlebara anya nke ya.

Nke a bụ isi ọgwụgwọ ndị ọzọ dọkịta gị nwere ike ikwu:

Ọgwụgwọ ndị ọzọ jikọtara ọnụ:

• Sofosbuvir na velpatasvir (Epclusa) - na-arụ ọrụ megide ụdị hepatitis C niile
• Ledipasvir na sofosbuvir (Harvoni) - tumadi maka ụdị 1, 4, 5, na 6
• Sofosbuvir na simeprevir - a na-ejikarị ribavirin eme ihe

Nhọrọ ọgwụgwọ ọhụrụ:

• Elbasvir na grazoprevir (Zepatier) - dị mma maka ndị nwere nsogbu akụrụ
• Daclatasvir na sofosbuvir - nhọrọ dose na-agbanwe agbanwe

Dọkịta gị ga-enyere gị aka ịghọta nke ọzọ nwere ike ịrụ ọrụ kacha mma maka ọnọdụ gị. Ihe dị ka ọrụ akụrụ gị, ọgwụ ndị ọzọ ị na-aṅụ, na mkpuchi mkpuchi gị na-ekere òkè n'ịhọrọ ọgwụgwọ kachasị mma maka gị.

Glecaprevir na Pibrentasvir ka mma karịa Sofosbuvir na Velpatasvir?

Ngwakọta abụọ ahụ dị oke irè ọgwụgwọ ọgbara ọhụrụ maka hepatitis C, nwere ọnụego ịga nke ọma karịa 95% n'ọtụtụ ndị ọrịa. Nhọrọ dị n'etiti ha na-abụkarị ọnọdụ onwe gị kama otu ịbụ nke ka mma. Dọkịta gị ga-atụle ọnọdụ gị iji chọpụta nhọrọ nke na-enye ezigbo nguzozi nke ịdị irè na nchekwa maka gị.

Glecaprevir na pibrentasvir nwere ike ịka mma n'ọnọdụ ụfọdụ n'ihi na ọ chọghị mgbanwe dose maka obere nsogbu akụrụ, ma nwee mmekọrịta ọgwụ ole na ole karịa ụfọdụ nhọrọ ndị ọzọ. Ọ na-emekwa ka obere mmetụta dị n'ọtụtụ ndị ọrịa, na-eme ka ọ dị mfe ịmecha usoro ọgwụgwọ zuru oke.

Sofosbuvir na velpatasvir, n'aka nke ọzọ, dịworị ogologo oge ma nwee nnukwu ahụmịhe ụwa. A ga-ahọrọ ya maka ndị nwere nnukwu ọrịa akụrụ ma ọ bụ ụfọdụ ọnọdụ ahụike dị mgbagwoju anya. Ọgwụ abụọ ahụ bụ ezigbo nhọrọ, dọkịta gị ga-enyere gị aka ikpebi nke na-adaba kacha mma na profaịlụ ahụike gị.

Ihe kachasị mkpa abụghị ọgwụ nke ka mma n'ụzọ echiche, kama nke ị nwere ike iji n'enweghị nsogbu ma mechaa nke ọma. Ọgwụgwọ abụọ ahụ agbanweela nlekọta hepatitis C ma na-enye nnukwu ohere nke ịgwọ ọrịa ahụ mgbe a na-aṅụ ya dị ka a tụrụ aro.

Ajụjụ A Na-ajụkarị Banyere Glecaprevir na Pibrentasvir

Glecaprevir na Pibrentasvir ọ dị mma maka ndị nwere ọrịa akụrụ?

Ee, ọgwụgwọ a na-adịkarị mma maka ndị nwere obere ma ọ bụ ọkara ọrịa akụrụ, ọ dịghịkwa achọ mgbanwe dose n'ọtụtụ ọnọdụ. Nke a bụ n'ezie otu n'ime uru nke njikọ a karịa ụfọdụ ọgwụgwọ hepatitis C ndị ọzọ. Otú ọ dị, ndị nwere nnukwu ọrịa akụrụ chọrọ nlekota pụrụ iche ma nwee ike ịchọ ụzọ ọgwụgwọ dị iche.

Dọkịta gị ga-enyocha ọrụ akụrụ gị site na ule ọbara tupu ịmalite ọgwụgwọ ma nwee ike ilekọta ya n'oge ọgwụgwọ. Ọ bụrụ na ị na-agba dialysis ma ọ bụ nwee nnukwu ọrịa akụrụ, ndị otu ahụike gị ga-arụkọ ọrụ gị ọnụ iji hụ na ọgwụgwọ dị mma ma dị irè. Ozi ọma bụ na ịgwọ hepatitis C nwere ike inye aka chebe akụrụ gị ka ha ghara imebi n'ọdịnihu.

Gịnị ka m ga-eme ma ọ bụrụ na m na-ewere Glecaprevir na Pibrentasvir n'ụzọ na-ezighị ezi?

Ọ bụrụ na ị na-ewere ihe karịrị dose gị edepụtara n'ụzọ na-ezighị ezi, kpọtụrụ dọkịta gị ma ọ bụ ebe njikwa nsí ozugbo, ọbụlagodi na ahụ gị dị mma. Ị takingụ ọgwụ a nke ukwuu nwere ike ịkpata nnukwu nsogbu imeju ma ọ bụ nsogbu ndị ọzọ, yabụ ọ dị mkpa ịnweta ndụmọdụ ahụike ozugbo.

Anwala ime ka overdose site n'ịwepụ dose gị na-esote ma ọ bụ were obere ọgwụgwọ ma emechaa. Kama, gaa n'ihu na usoro dosing gị mgbe niile dị ka dọkịta gị nyere iwu. Debe ngwugwu ọgwụgwọ ahụ gị mgbe ị na-achọ enyemaka ahụike, n'ihi na ozi a nwere ike ịba uru maka ndị na-ahụ maka ahụike.

Iji gbochie overdoses na-ezighi ezi, tụlee iji onye nhazi pill ma ọ bụ ịtọ ihe ncheta ekwentị. Ọ bụrụ na ị na-ebi na ndị ọzọ, mee ka ha mara banyere usoro ọgwụgwọ gị ka ha wee nwee ike inyere gị aka idobe ma ọ dị mkpa.

Gịnị ka m ga-eme ma ọ bụrụ na m na-efunahụ dose nke Glecaprevir na Pibrentasvir?

Ọ bụrụ na ị tụfuru otu dose ma ọ bụrụ na ọ dịghị ihe karịrị awa 18 kemgbe oge a kara aka, were dose ahụ ị tụfuru ozugbo i chetara, na nri. Ọ bụrụ na ọ dị ihe karịrị awa 18, gbaghara dose ahụ ị tụfuru wee were dose gị na-esote n'oge a na-ahụkarị. Etinyela doses abụọ n'otu oge iji mezie dose ị tụfuru.

Ịtụfu doses mgbe ụfọdụ agaghị emebi ọgwụgwọ gị, mana gbalịa idobe usoro dịka o kwere mee. Ọ bụrụ na ị na-echefukarị doses, gwa dọkịta gị okwu gbasara atụmatụ iji nyere gị aka icheta. Ụfọdụ ndị na-enweta ihe ịga nke ọma na mkpu ekwentị, ndị nhazi ọgwụ, ma ọ bụ ijikọ ọgwụ ha na usoro kwa ụbọchị dị ka nri.

Ọ bụrụ na ị tụfuru ihe karịrị doses ole na ole n'oge ọgwụgwọ gị, kpọtụrụ onye na-ahụ maka ahụike gị. Ha nwere ike ịchọ ịgbatị oge ọgwụgwọ gị ma ọ bụ nyochaa gị nke ọma iji hụ na ọgwụ ahụ ka na-arụ ọrụ nke ọma.

Kedu mgbe m ga-akwụsị iwere Glecaprevir na Pibrentasvir?

Naanị ị ga-akwụsị iwere ọgwụ a mgbe dọkịta gị gwara gị, na-emekarị mgbe ịmechara usoro gị edepụtara nke izu 8 ruo 16. Ịkwụsị n'oge, ọbụlagodi na ị na-eche na ị dị nnọọ mma, nwere ike ikwe ka nje ahụ laghachi ma nwee ike ịmepụta nguzogide na ọgwụ ahụ. Nke a nwere ike ime ka ọgwụgwọ n'ọdịnihu sie ike ma ghara ịdị irè.

Dọkịta gị ga-enye iwu nyocha ọbara ihe dị ka izu 12 ka ị gụchara ọgwụgwọ iji kwado na ewepụrụ nje ahụ n'ahụ gị. Ule a, nke a na-akpọ nzaghachi virologic na-adịgide adịgide (SVR), na-egosi ma ọgwụgwọ ahụ ọ gara nke ọma. Naanị mgbe nkwenye a gasịrị ka ị ga-enwe obi ike na agwọla hepatitis C.

Ọ bụrụ na ị na-enwe mmetụta dị n'akụkụ nke na-eme ka ịchọọ ịkwụsị ọgwụgwọ, gwa dọkịta gị okwu mbụ. Ha nwere ike inyere aka ijikwa mmetụta dị n'akụkụ ma ọ bụ gbanwee atụmatụ ọgwụgwọ gị. Cheta na oge ọgwụgwọ a dị mkpụmkpụ ma e jiri ya tụnyere ọgwụgwọ hepatitis C ochie, na imecha ya na-enye gị ohere kacha mma nke ịgwọ ọrịa.

\u01cbm\u1ecb m\u1ee5 nwere ike \u1ee5\u1ecb mmanya na-egbu egbu mgbe m na-a\u1ee5 Glecaprevir na Pibrentasvir?

\u1ee4t\u1ee5 \u1ee5\u1ee5 mma izere mmanya na-egbu egbu kpamkpam mgbe \u1ee5 na-a\u1ee5 \u1ee5gw\u1ee5 \u1ee5gw\u1ee5 a na maka \u1ecb\u1ecb\u1ecb ole na ole mgbe agw\u1ee5chara \u1ee5gw\u1ee5. Mmanya na-egbu egbu nwere ike imebi imeju g\u1ecb, ebe \u1ee5 na-agw\u1ee5 \u1ecb\u1ecb nje imeju, \u1ee5 ch\u1ee5\u1ee5r\u1ee5 inye imeju g\u1ecb ohere kacha mma iji gw\u1ee5. \u1ecb\u1ecb\u1ecb mmanya na-egbu egbu nwere ike igbochi usoro mgbake imeju g\u1ecb.

Mmanya na-egbu egbu nwekwara ike ime ka \u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u1ecb\u